Nonclinical and Translational /Early Phase Clinical Development Track at DIA's 49th Annual Meeting

 

	How can we optimize the transition from Preclinical to Clinical Research?
	How can we design a strategy for efficient, rapid and inexpensive assessment of drug-related QT effects?
	What is the Impact of Subject Dual Enrollment on Study Data Validity?
	What are the opportunities for drug-induced vacsulitis biomarkers and translational medicine research areas.
	What are the benefits of PET imaging in preclinical and clinical therapeutic drug development?
	What is the impact of Pharmacometrics in Preclinical to Early Phase Clinical Development?
	When are human abuse liability studies indicated by FDA?
	What is the impact of regional cooperation on drug development innovation in China and Latin America?